Previous 10 | Next 10 |
SAN DIEGO, Aug. 03, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it will report second quarter 2021 financial results and provide...
aTyr Pharma (NASDAQ:LIFE) announces that the U.S. Patent and Trademark Office (USPTO) has granted a patent covering methods for the use of histidyl-tRNA synthetase Fc fusion proteins for reducing inflammatory response in the lung. The patent covers the use of the company’s le...
SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the U.S. Patent and Trademark Office (USPTO) has granted a paten...
LONDON, UK / ACCESSWIRE / July 27, 2021 / Love Hemp Group PLC (AQSE:LIFE)(OTCQB:WRHLF) , one of the UK's leading CBD and hemp product suppliers, is pleased to provide an unaudited post-close trading update for the year ended 30 June 2021 ('FY21' or 'the Period'). Financial Highlights Love...
aTyr Pharma (LIFE) announces that the last patient has completed their last visit in the company’s Phase 1b/2a clinical trial of its lead therapeutic candidate, ATYR1923, in patients with pulmonary sarcoidosis, a major form of interstitial lung disease.The company expects to repor...
Results from proof-of-concept study are expected in September 2021. SAN DIEGO, July 08, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today ann...
LONDON, ENGLAND / ACCESSWIRE / June 30, 2021 / For the purposes of the Financial Conduct Authority's Disclosure Guidance and Transparency Rules, Love Hemp (AQSE:LIFE) (OTCQB:WRHLF) announces that the Company has 829,145,188 ordinary shares of 1p each in issue ('Ordinary Shares'), each shar...
Innovative Russian pharmaceutical developer, Pharmsynthez PJSC (MOEX:LIFE), and global alternative investment group, LDA Capital, enter into a Put Option Agreement for 800 million rubles to help finance the development of Pharmsynthez’s pioneering projects over the next 36 months...
Event will feature Dr. Daniel Culver, Director of the Interstitial Lung Disease Program at the Cleveland Clinic. Conference call and webcast scheduled for Tuesday June 29 th at 5:00pm ET/2:00pm PT. SAN DIEGO, June 23, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. ...
Three-Year Endorsement Agreement Secured with Anthony Joshua OBE Heavyweight Champion of the World and Olympic Gold Medallist to Become Key Shareholder LONDON, UK / ACCESSWIRE / June 21, 2021 / Love Hemp Group PLC (AQSE:LIFE)(OTCQB:WRHLF) , one of the UK's leading CBD and hemp produ...
News, Short Squeeze, Breakout and More Instantly...
SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today ann...
SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the c...
Independent data and safety monitoring board (DSMB) recommends continuation of study without any modifications. Findings further support favorable safety profile of efzofitimod. SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or the “Compa...